INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Jun 30, 2026. Filed Jul 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 29, 2026

IART$14.53+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

(Dollars in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Total revenue, net	$418,761	$415,605	$810,679	$798,258
Costs and expenses:
Cost of goods sold	199,017	206,273	373,953	394,494
Research and development	24,253	26,997	47,754	51,725
Selling, general and administrative	172,436	179,890	350,671	361,387
Intangible asset amortization	3,770	3,754	7,546	7,458
Goodwill impairment charge	—	511,365	—	511,365
Total costs and expenses	399,476	928,279	779,924	1,326,429
Operating income (loss)	19,285	(512,674)	30,755	(528,171)
Interest income	4,267	4,710	8,372	9,130
Interest expense	(22,994)	(21,042)	(45,459)	(39,857)
Other income (expense), net	4,186	(1,946)	8,665	(2,090)
Income (loss) before income taxes	4,744	(530,952)	2,333	(560,988)
Provision (benefit) for income taxes	262	(46,879)	2,467	(51,622)
Net income (loss)	$4,482	$(484,073)	$(134)	$(509,366)
Net income (loss) per share
Basic	$0.06	$(6.31)	$—	$(6.65)
Diluted	$0.06	$(6.31)	$—	$(6.65)
Weighted average common shares outstanding (See Note 12):
Basic	77,293	76,695	77,122	76,579
Diluted	78,168	76,695	77,122	76,579
Comprehensive loss (See Note 13)	(4,775)	(490,874)	(10,254)	$(512,702)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.